Medilink TherapeuticsGood news for BioNTech SE: The safety study of the ADC BNT326/YL202 developed by MediLink Therapeutics, which was suspended by the FDA in mid-June, will continue.
Tag Archive for: BioNTech
BioNtech SE has reported preliminary Phase I/II results with BNT211-01 (NEO-PTC-01) and CarVAC at ESMO conference in Madrid
BioNTech has entered the ADC field with an exclusive license and collaboration agreement with Chinas DualityBio Ltd for two antibody-drug conjugate (ADC) assets.
BioNTech SE will pay £562m in cash to acquire its former partner InstaDeep Ltd. to expand its capabilities in AI-based drug discovery.
Renewed focus on cancer: COVID-19 vaccine company BioNTech SE (Nasdaq: BNTX) and Ryvu Therapeutics S.A., located in Krakow (Warsaw Stock Exchange: RVU), a Polish clinical-stage cancer therapeutics development company, announced that the companies have entered into a research collaboration for several multi-target immunotherapy programmes, as well as an exclusive licensing agreement for Ryvu’s STING agonist portfolio as stand-alone small molecules.